Increasing reports of von Willebrand disease, disseminated intravascular clotting, and histological lesions in patients treated with hydroxyethyl starch (HES) emerged between 1975–2003. But this wasn’t the first time the safety of HES had been bought into question, as Alexander et al., detailed in what was described as a quarter-century enigma.
Learn more about how these warnings and safety concerns began to escalate in 2012.Timeline homepage
Alternatively login via
Back to epgonline.org